Clomipramine
Tricyclic antidepressant for OCD, depression, panic disorder and narcolepsy
Quick Facts: Clomipramine
Key Takeaways
- Clomipramine is considered the gold standard tricyclic antidepressant for obsessive-compulsive disorder (OCD), with response rates of 40–60% in clinical trials.
- It takes 2–4 weeks to notice effects for depression and up to 12 weeks for full OCD benefit – do not stop treatment prematurely.
- Never combine clomipramine with MAO inhibitors, SSRIs, or SNRIs due to the risk of life-threatening serotonin syndrome.
- Common side effects include dry mouth, constipation, dizziness, drowsiness, and weight gain – most are mild and improve over time.
- Treatment should never be stopped abruptly – the dose must be tapered gradually under medical supervision to avoid withdrawal symptoms.
What Is Clomipramine and What Is It Used For?
Quick Answer: Clomipramine is a tricyclic antidepressant (TCA) that works by increasing serotonin and norepinephrine levels in the brain. It is primarily prescribed for obsessive-compulsive disorder (OCD), depression, panic disorder, phobic anxiety, and narcolepsy.
Clomipramine belongs to the dibenzazepine subgroup of tricyclic antidepressants. Its primary mechanism of action involves potent inhibition of serotonin (5-HT) reuptake at the synaptic cleft, with its active metabolite desmethylclomipramine additionally inhibiting norepinephrine reuptake. This dual mechanism distinguishes clomipramine from most other TCAs and contributes to its particularly strong efficacy in treating OCD, a condition closely linked to serotonergic dysfunction.
Clomipramine is included in the World Health Organization (WHO) Model List of Essential Medicines, reflecting its global importance in treating psychiatric disorders. It has been used clinically since the 1960s and remains a cornerstone of OCD pharmacotherapy, particularly in cases where selective serotonin reuptake inhibitors (SSRIs) have proven insufficient.
Approved Indications
Clomipramine is prescribed for several psychiatric and neurological conditions:
- Obsessive-compulsive disorder (OCD) – Clomipramine is regarded as one of the most effective medications for OCD. Multiple meta-analyses, including Cochrane reviews, have demonstrated its superiority over placebo and comparable or slightly superior efficacy to SSRIs for this indication. It reduces intrusive thoughts (obsessions) and repetitive behaviors (compulsions).
- Major depressive disorder – As a tricyclic antidepressant, clomipramine has well-established antidepressant properties. It is typically reserved for moderate-to-severe depression or when newer antidepressants have not provided adequate relief.
- Panic disorder – Effective in reducing the frequency and severity of panic attacks, including panic disorder with or without agoraphobia (fear of open or crowded spaces).
- Phobic anxiety disorders – Used in the treatment of specific phobias and social anxiety when these conditions significantly impair daily functioning.
- Narcolepsy – Clomipramine helps manage cataplexy (sudden muscle weakness triggered by emotions) and other symptoms of narcolepsy, a neurological condition characterized by sudden, uncontrollable sleep episodes.
While these are the principal approved indications, clinicians may sometimes prescribe clomipramine off-label for conditions such as chronic pain syndromes, premature ejaculation, or enuresis (bedwetting) in children, where evidence supports potential benefit. Any off-label use should be carefully discussed with the prescribing physician.
What Should You Know Before Taking Clomipramine?
Quick Answer: Clomipramine must not be taken with MAO inhibitors or immediately after a heart attack. Before starting treatment, inform your doctor about any history of epilepsy, heart problems, glaucoma, liver or kidney disease, thyroid disorders, or prostate enlargement.
Contraindications
Clomipramine must not be taken in the following circumstances:
- Hypersensitivity to clomipramine, any other tricyclic antidepressant of the dibenzazepine group, or any of the excipients in the formulation.
- Concurrent use of MAO inhibitors – Taking clomipramine together with monoamine oxidase inhibitors (MAOIs), including moclobemide, is strictly contraindicated due to the risk of fatal serotonin syndrome. A washout period of at least 14 days is required when switching between these drug classes.
- Concurrent use of SSRIs or SNRIs – Combining clomipramine with selective serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine, fluvoxamine) or serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine) is contraindicated for the same reason.
- Recent myocardial infarction – Clomipramine is contraindicated in patients who have recently had a heart attack due to its cardiovascular effects, including potential arrhythmias and conduction disturbances.
Warnings and Precautions
Before starting clomipramine, it is essential to discuss the following conditions and risk factors with your prescribing physician:
Antidepressants, including clomipramine, may increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults under 25. This risk is particularly elevated during the initial weeks of treatment or when the dose is changed. Patients and their caregivers should closely monitor for worsening depression, unusual changes in behavior, agitation, or suicidal ideation. Seek immediate medical attention if these symptoms occur.
- Epilepsy or seizure history – Clomipramine can lower the seizure threshold. Patients with a history of seizures require careful monitoring and possible dose adjustments.
- Cardiac arrhythmias or conduction disorders – The drug can affect cardiac conduction and may cause or worsen arrhythmias. An ECG may be recommended before and during treatment, especially in elderly patients.
- Glaucoma (narrow-angle) – Clomipramine has anticholinergic properties that can increase intraocular pressure, potentially worsening glaucoma.
- Liver or kidney disease – Impaired hepatic or renal function may alter drug metabolism and require dose adjustments.
- Urinary retention or prostatic enlargement – The anticholinergic effects can exacerbate difficulty urinating.
- Hyperthyroidism – Overactive thyroid increases sensitivity to the cardiovascular effects of tricyclic antidepressants.
- Schizophrenia or other psychotic disorders – Clomipramine may exacerbate psychotic symptoms in vulnerable patients.
- Pheochromocytoma – This adrenal gland tumor creates a risk of hypertensive crisis when combined with tricyclic antidepressants.
- Heavy alcohol use – Alcohol can potentiate the sedative effects of clomipramine and increase the risk of seizures.
- Bleeding tendency – Clomipramine can affect platelet function and may increase the risk of bleeding, particularly when combined with anticoagulants, aspirin, or NSAIDs.
Clomipramine commonly causes dry mouth, which increases the risk of dental cavities over long-term use. Maintain rigorous oral hygiene and attend regular dental check-ups. The medication can also reduce tear production; contact lens wearers may experience discomfort and should consult their doctor if eye irritation develops.
Regular monitoring by your doctor is important during clomipramine therapy. This may include blood tests, blood pressure measurements, and cardiac function assessments to ensure the dose remains appropriate and that side effects are minimized. Before any surgery or dental procedure, inform the treating physician or dentist that you are taking clomipramine.
Clomipramine can increase photosensitivity. Avoid prolonged direct sun exposure, protect your skin with clothing, and use sunglasses during treatment. As with all antidepressants in this class, clomipramine does not provide immediate symptom relief. Therapeutic effects typically develop over several weeks. It is critical to continue treatment as prescribed even if initial improvement seems slow.
Children and Adolescents
Clomipramine should not be used for treating depression in children and adolescents under 18 years of age. Studies of antidepressant medications in this age group have shown an increased risk of suicidal behavior, self-harm, and hostility. However, a physician may prescribe clomipramine to patients under 18 for OCD if the potential benefits clearly outweigh the risks, as it is one of the few medications with established efficacy for childhood OCD. The long-term effects on growth, maturation, cognitive development, and behavioral development in this population have not been fully established.
Elderly Patients
Older adults generally require lower doses of clomipramine than younger patients. The dose should be initiated at the lowest effective level and increased cautiously. Elderly patients are more susceptible to the anticholinergic, cardiovascular, and sedative effects of the drug. Particular attention should be paid to orthostatic hypotension (dizziness when standing up), which increases the risk of falls in this population.
Pregnancy and Breastfeeding
Clomipramine crosses the placental barrier and may affect fetal development. The active substance also passes into breast milk. Women who are pregnant, planning pregnancy, or breastfeeding should always consult their doctor before starting or continuing treatment. The decision to use clomipramine during pregnancy should weigh the benefits of treating the mother's condition against the potential risks to the fetus. In some cases, the untreated psychiatric condition itself may pose greater risks to both mother and child than the medication.
Driving and Operating Machinery
Clomipramine can cause drowsiness, reduced alertness, and blurred vision, particularly during the initial phase of treatment or after dose adjustments. Patients experiencing these effects should not drive, operate heavy machinery, or perform tasks requiring heightened attention. These effects often diminish as the body adjusts to the medication, but patients should exercise caution and follow their physician's guidance on resuming these activities.
How Does Clomipramine Interact with Other Drugs?
Quick Answer: Clomipramine has significant interactions with MAO inhibitors, SSRIs, SNRIs, antiepileptics, antipsychotics, anticoagulants, and several other medications. Always inform your doctor about all medications you take, including over-the-counter drugs and herbal supplements.
Drug interactions are a major safety consideration with clomipramine. Because it affects multiple neurotransmitter systems and is metabolized by cytochrome P450 liver enzymes, it can interact with a wide range of medications. Some interactions can be life-threatening. Always provide your prescribing physician and pharmacist with a complete list of all medications, supplements, and herbal products you are currently taking.
Major Interactions (Avoid Combination)
| Drug / Drug Class | Interaction Effect | Risk Level |
|---|---|---|
| MAO inhibitors (moclobemide, phenelzine, tranylcypromine) | Risk of fatal serotonin syndrome – high fever, seizures, cardiovascular collapse | Contraindicated |
| SSRIs (fluoxetine, paroxetine, fluvoxamine) | Serotonin syndrome risk; SSRIs also inhibit clomipramine metabolism, raising blood levels | Contraindicated |
| SNRIs (venlafaxine, duloxetine) | Serotonin syndrome risk from combined serotonergic activity | Contraindicated |
| Buprenorphine / Opioids | Risk of serotonin syndrome; enhanced sedation and respiratory depression | Major |
Moderate Interactions (Use with Caution)
| Drug / Drug Class | Interaction Effect | Clinical Action |
|---|---|---|
| Clonidine | Reduced antihypertensive effect of clonidine | Monitor blood pressure; consider alternative antihypertensive |
| Quinidine | Inhibits clomipramine metabolism; increased blood levels and toxicity risk | Dose reduction of clomipramine may be needed |
| Warfarin and other anticoagulants | Increased bleeding risk; altered anticoagulant effect | Monitor INR closely; adjust warfarin dose as needed |
| Antiepileptics (phenobarbital, valproic acid) | Phenobarbital may reduce clomipramine levels; valproic acid may increase them | Monitor drug levels and seizure control |
| Cimetidine | Inhibits clomipramine metabolism, increasing plasma levels | Consider switching to alternative antacid (e.g., ranitidine, PPI) |
| Antipsychotics (e.g., levomepromazine) | Enhanced sedation; potential increase in clomipramine blood levels | Monitor for excessive sedation; adjust doses |
| Epinephrine, norepinephrine, dopamine | Enhanced cardiovascular effects (hypertension, arrhythmia) | Inform anesthesiologist before procedures |
| St. John's Wort | Reduced clomipramine levels; possible serotonin syndrome | Avoid combination |
| Grapefruit juice | May increase clomipramine blood levels via CYP3A4 inhibition | Avoid regular consumption of large amounts |
| NSAIDs (ibuprofen, naproxen) and Aspirin | Increased bleeding risk | Use with caution; monitor for signs of bleeding |
| Cholestyramine / Colestipol | May reduce clomipramine absorption | Separate administration by at least 2 hours |
Smoking induces CYP1A2 liver enzymes, which can increase the metabolism of clomipramine. If you start or stop smoking during treatment, your doctor may need to adjust the dose. Always inform your prescriber about changes in smoking habits.
Clomipramine can be taken with or without food. However, taking it with a meal may help reduce gastrointestinal side effects such as nausea. Consistent timing of doses relative to meals is recommended for stable blood levels.
What Is the Correct Dosage of Clomipramine?
Quick Answer: The effective maintenance dose for most adults is 25–150 mg per day. Treatment is started at a low dose and gradually increased. Your doctor will determine the appropriate dose based on your condition, age, and response to therapy.
Clomipramine dosing is highly individualized. The appropriate dose depends on the patient's age, the specific condition being treated, disease severity, and individual tolerance. Treatment always begins with a low starting dose that is gradually increased to minimize side effects and allow the body to adjust. Similarly, when discontinuing treatment, the dose should be tapered slowly to avoid withdrawal symptoms.
Adults
Standard Adult Dosing
- Starting dose: 25 mg once daily, or 10 mg in patients sensitive to side effects
- Dose titration: Increase by 25 mg every few days as tolerated over the first 2 weeks
- Maintenance dose: 25–150 mg per day, depending on the indication
- Maximum dose: Up to 250 mg daily in severe cases under specialist supervision
- Administration: Can be given as a single daily dose or divided into 2–3 doses. The extended-release (Retard) formulation is typically given once daily.
For OCD specifically, higher doses within the therapeutic range (100–250 mg/day) are often required for adequate symptom control. The APA practice guidelines recommend maintaining the effective dose for at least 1–2 years before considering gradual discontinuation, as OCD tends to be a chronic condition with high relapse rates.
Children and Adolescents
Pediatric Dosing (OCD only, under specialist supervision)
- Not recommended for treating depression in patients under 18 years
- For OCD: May be initiated at 25 mg daily, with gradual increases under strict medical supervision
- Dose is generally lower than adults and based on body weight
- Close monitoring for suicidal ideation and behavioral changes is mandatory
Elderly Patients
Elderly Dosing
- Starting dose: 10 mg once daily
- Titration: Increase more slowly than in younger adults (every 5–7 days)
- Maintenance dose: Generally lower than standard adult doses
- Careful monitoring for orthostatic hypotension, sedation, and anticholinergic effects
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the one you missed. If you have any concerns, contact your doctor or pharmacist for guidance.
Overdose
A clomipramine overdose is a medical emergency. Symptoms may appear rapidly or be delayed and include severe drowsiness, agitation, hallucinations, rapid or slow or irregular heartbeat, seizures, high fever, and respiratory depression. If overdose is suspected, contact emergency medical services or a poison control center immediately. Do not wait for symptoms to appear.
Tricyclic antidepressant overdoses are among the most dangerous prescription drug overdoses. Even moderate overdoses can be life-threatening due to the cardiac toxicity of these medications. Patients who accidentally or intentionally take more than the prescribed amount should seek emergency medical attention without delay.
Discontinuing Treatment
Clomipramine should never be stopped abruptly. The dose must be reduced gradually over several weeks under medical supervision. Sudden discontinuation can cause a withdrawal syndrome with symptoms including:
- Nausea and vomiting
- Gastrointestinal disturbances (diarrhea, abdominal cramps)
- Tremor and dizziness
- Excessive sweating
- Sleep disturbances (insomnia, vivid dreams)
- Irritability and anxiety
- General malaise and flu-like symptoms
Your physician will create a tapering schedule tailored to your individual needs, typically reducing the dose by small increments every 1–2 weeks. If withdrawal symptoms occur despite gradual tapering, the dose may be temporarily increased before continuing the taper more slowly.
How to Take Clomipramine
Standard (coated) tablets should be swallowed whole with plenty of water. The extended-release (Retard) tablets can be swallowed whole or divided along the score line but must not be crushed or chewed, as this would destroy the controlled-release mechanism and potentially cause a rapid release of the entire dose. Clomipramine may be taken with or without food.
What Are the Side Effects of Clomipramine?
Quick Answer: The most common side effects include dry mouth, constipation, dizziness, drowsiness, tremor, blurred vision, nausea, weight gain, and sweating. Most side effects are dose-dependent and tend to diminish over time as the body adjusts to the medication.
Like all medications, clomipramine can cause side effects, although not everyone experiences them. Side effects are generally most pronounced during the initial weeks of treatment and often subside as the body adapts. Many side effects are related to the drug's anticholinergic, antihistaminic, and adrenergic blocking properties. Your doctor has determined that the benefits of treatment outweigh the potential risks for your specific condition.
Very Common
Affects more than 1 in 10 people
- Dizziness and lightheadedness
- Tremor (fine shaking of hands)
- Headache
- Muscle twitching (myoclonus)
- Blurred vision and visual disturbances
- Nausea
- Dry mouth
- Constipation
- Difficulty urinating
- Sexual dysfunction (erectile difficulties, delayed ejaculation)
- Drowsiness and fatigue
- Increased appetite and weight gain
- Excessive sweating
- Restlessness
Common
Affects 1 in 10 to 1 in 100 people
- Anxiety and agitation
- Aggression and confusion
- Sleep disturbances and nightmares
- Memory problems and difficulty concentrating
- Personality changes
- Muscle weakness
- Pupil dilation (mydriasis)
- Tinnitus (ringing in the ears)
- Palpitations and hot flushes
- Vomiting, abdominal discomfort, and diarrhea
- Taste changes
- Skin rash, itching, and photosensitivity reactions
- Frequent yawning
- Galactorrhea (breast milk discharge)
- Gynecomastia (breast enlargement in males)
- Orthostatic hypotension (dizziness on standing)
- Decreased appetite
Uncommon
Affects 1 in 100 to 1 in 1,000 people
- Seizures (convulsions)
- Ataxia (difficulty coordinating movements)
- Cardiac arrhythmias (irregular heartbeat)
Rare
Affects fewer than 1 in 1,000 people
- Glaucoma (increased eye pressure)
- Gastrointestinal bleeding
- Jaundice (yellowing of the skin and eyes)
- Edema (fluid retention and swelling)
- Erythema (skin redness)
- Hair loss (alopecia)
- Mucosal bleeding (skin and mucous membranes)
- Allergic reactions
- High fever
Very Rare
Affects fewer than 1 in 10,000 people
- Neuroleptic malignant syndrome (muscle rigidity, high fever, altered consciousness) – requires immediate medical attention
The following side effects have been reported but their exact frequency cannot be determined from available data: serotonin syndrome (agitation, confusion, diarrhea, high body temperature, elevated blood pressure, excessive sweating, rapid heartbeat), akathisia (inability to sit still), involuntary movements, rhabdomyolysis (muscle breakdown as a complication of neuroleptic malignant syndrome), suicidal thoughts or behavior, elevated prolactin levels, and delayed or absent ejaculation.
An increased risk of bone fractures has been observed in patients taking this type of medication. If you experience any side effects that concern you, or if existing side effects worsen, consult your doctor or pharmacist promptly. Most side effects do not require specific medical treatment and resolve as the body adjusts to the medication.
Contact your doctor urgently or go to the nearest emergency department if you experience: yellowing of the skin (jaundice), severe skin reactions (rash, redness), high fever with sore throat, loss of balance, severe eye pain, severe abdominal pain, muscle weakness or rigidity, muscle cramps, difficulty urinating (retention), breast swelling or discharge, rapid or irregular pulse, speech difficulties, confusion, hallucinations, or seizures.
How Should You Store Clomipramine?
Quick Answer: Store clomipramine out of reach of children. Tablets have no special storage requirements; 25 mg tablets should be kept in their original packaging as they are moisture-sensitive. Do not use after the expiry date.
Proper storage of medications is essential to maintain their efficacy and safety. Clomipramine should always be kept out of the sight and reach of children to prevent accidental ingestion, which can be extremely dangerous given the toxicity of tricyclic antidepressants in overdose.
- 10 mg tablets and 75 mg extended-release tablets: No special storage requirements.
- 25 mg tablets: Store in the original packaging to protect from moisture.
- Do not use after the expiry date printed on the carton. The expiry date refers to the last day of the indicated month.
- Do not dispose of medications via the drain or household waste. Return unused or expired medications to your pharmacy for safe disposal to protect the environment.
If you notice any visible changes in the appearance of the tablets, such as discoloration, unusual odor, or crumbling, do not use them and consult your pharmacist.
What Does Clomipramine Contain?
Quick Answer: The active substance is clomipramine hydrochloride. Inactive ingredients vary by formulation and include lactose monohydrate, sucrose, magnesium stearate, corn starch, and various coating agents.
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to certain excipients.
Active Ingredient
The active pharmaceutical ingredient in all formulations is clomipramine hydrochloride, available in strengths of 10 mg, 25 mg (coated tablets) and 75 mg (extended-release tablets).
Inactive Ingredients (Excipients)
| Formulation | Key Excipients | Allergen Notes |
|---|---|---|
| Coated tablets (10 mg, 25 mg) | Lactose monohydrate, sucrose, corn starch, magnesium stearate, microcrystalline cellulose, povidone, copovidone, hypromellose, macrogol, iron oxide (E172), titanium dioxide (E171), colloidal anhydrous silica, stearic acid (25 mg), glycerol (25 mg), talc | Contains lactose and sucrose – consult your doctor if you have sugar intolerance |
| Extended-release tablets (75 mg) | Calcium hydrogen phosphate dihydrate, calcium stearate, colloidal anhydrous silica, Eudragit ED (polyacryl/methacrylate copolymer), hypromellose, macrogolglycerol hydroxystearate, iron oxide (E172), titanium dioxide (E171), talc | Contains macrogolglycerol hydroxystearate, which may cause stomach upset and diarrhea |
Tablet Appearance
- 10 mg coated tablet: Pale yellow, triangular, biconvex. Dimensions approximately 5.8 mm high, 3.3 mm thick.
- 25 mg coated tablet: Pale yellow, round, biconvex. Diameter approximately 5.5 mm.
- 75 mg extended-release tablet: Pink, oblong with a score line, marked "CG" and "GD".
Available pack sizes include 20, 30, and 100 tablets depending on the strength and formulation. Not all pack sizes may be available in every market.
Frequently Asked Questions About Clomipramine
Medical References & Sources
All information is based on international medical guidelines and peer-reviewed research. Evidence level: 1A (systematic reviews of randomized controlled trials).
- Cochrane Database of Systematic Reviews (2023). Clomipramine versus other antidepressive agents for obsessive compulsive disorder. Cochrane Library. Systematic review comparing efficacy and tolerability of clomipramine versus alternative antidepressants for OCD.
- American Psychiatric Association (2023). Practice Guidelines for the Treatment of Obsessive-Compulsive Disorder. APA Practice Guidelines. Comprehensive evidence-based recommendations for OCD pharmacotherapy including clomipramine positioning.
- National Institute for Health and Care Excellence (2023). Obsessive-compulsive disorder and body dysmorphic disorder: recognition and management. NICE Clinical Guideline CG31 (updated). UK national guidelines on OCD treatment including clomipramine use.
- British Association for Psychopharmacology (2023). Evidence-Based Guidelines for the Pharmacological Treatment of OCD. Journal of Psychopharmacology. Guidelines addressing clomipramine dosing, monitoring, and combination strategies.
- World Health Organization (2023). WHO Model List of Essential Medicines – 23rd List. WHO. Clomipramine listed as an essential medicine for obsessive-compulsive disorder.
- European Medicines Agency. Clomipramine Summary of Product Characteristics (SmPC). EMA. Official European regulatory information on approved indications, dosing, contraindications, and pharmacokinetics.
- U.S. Food and Drug Administration. Anafranil (clomipramine hydrochloride) prescribing information. FDA. Approved U.S. labeling including black box warning on suicidality in young adults.
- British National Formulary (BNF). Clomipramine hydrochloride monograph. NICE/BNF. Clinical drug information including dosing, interactions, and monitoring requirements.
- Skapinakis P, et al. (2016). Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 3(8), 730–739. Network meta-analysis comparing efficacy of OCD treatments.
- Stahl SM (2021). Stahl's Essential Psychopharmacology: Prescriber's Guide, 7th edition. Cambridge University Press. Comprehensive prescriber reference for clomipramine pharmacology and clinical use.
Editorial Team & Medical Review
This article has been reviewed by our medical editorial team, which includes board-certified specialists in clinical pharmacology and psychiatry.
Medical Review Board
Board-certified specialists in psychiatry and clinical pharmacology. Content verified against international guidelines (WHO, EMA, FDA, NICE, APA, BAP).
Evidence Standards
Level 1A evidence based on systematic reviews and meta-analyses of randomized controlled trials. GRADE evidence framework applied.
Editorial Independence
No pharmaceutical company funding or sponsorship. All medical content is independently reviewed and free from commercial influence.
Review Schedule
Published: . Last reviewed: . Next review scheduled within 12 months or when new evidence emerges.